Back to Top

Information For Authors

Please be sure to CLICK HERE to review our peer review and journal policies.

CLICK HERE for Article Types, Word, and Figure/Table Limits

After reading all instructions below, CLICK HERE to begin your submission (https://mc.manuscriptcentral.com/fpsam)

Manuscript Preparation

Facial Plastic Surgery & Aesthetic Medicine welcomes format-neutral manuscripts for first-time submissions. Newly submitted manuscripts will not be un-submitted for formatting issues.  However, after the initial peer review process, revised submissions must follow correct journal formatting and file guidelines, as described in the Instructions for Authors.

ORCID IDs

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

CLICK HERE to see JOURNAL STANDARDS AND BEST PRACTICES STATEMENT

CLICK HERE to view the Journal’s PEER REVIEW POLICIES

ATTENTION:  To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

Use of English Language
All submissions must be in English. Appropriate use of English is a requirement for review and publication in Facial Plastic Surgery & Aesthetic Medicine. To support non-native speakers, Mary Ann Liebert, Inc., has partnered with Editage to provide language editing and translation services for a fee prior to official submission. To learn more about the services, please visit the Liebert Author Services website. Please note that employing the use of such services is not mandatory and using it, or any other language editing service, does not guarantee the acceptance of any paper. All submissions are subject to peer review.

DETERMINE AUTHORSHIP

  • Authorship is to be determined prior to submission of any manuscript. 
  • All authors listed on a submitted manuscript should be responsible for a significant part of the manuscript.
  • All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content.
  • Any author whose name appears on a paper assumes responsibility and accountability for the results.
  • CLICK HERE to see AUTHORSHIP QUALIFICATIONS AND RESPONSIBILITIES for definitions and further detailed information.

COPYRIGHT / LICENSING

CLICK HERE for information on Copyright, Licensing, Reuse and Open Access options.

SUBMISSION PROCESS

CLICK HERE for Article Types, Word, and Figure/Table Limits

After reading all instructions below, CLICK HERE to begin your submission (https://mc.manuscriptcentral.com/fpsam)

Papers should contain original data concerning the course (prognosis), cause (etiology), diagnosis, treatment, prevention, or economic analysis of a clinical disorder or an intervention to improve the quality of healthcare.

When you are ready to submit your manuscript for peer review, be prepared to:

  • Enter the title of the article (be sure to read the section entitled, "Create an Effective Title" below)
  • Enter the full names and institutional affiliations of ALL authors and their correlating institutional affiliations and e-mail addresses
  • Identify the corresponding author
  • Enter a running title of no more than 45 characters (including spaces)
  • Provide a structured Abstract of no more than 250 words, stating the background, methods, results (including the sample size), and conclusions drawn from the study
  • Enter 3–5 keywords or phrases for identifying areas of expertise for peer review
  • Enter 3–5 search terms for discoverability in search engines
  • Supply the names and valid institutional e-mail addresses of at least five potential preferred
     reviewers familiar with the field. Please ensure that preferred reviewers are not from your university or institution with whom you have collaborated. Anyone whom the author does not want to be considered should also be named as a non-preferred reviewer, however, ultimate reviewer selection is at the Editor’s discretion
  • Confirm that the material has not been published or submitted for publication elsewhere

PREPARING YOUR PAPER

All manuscripts must be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.

Please be sure to CLICK HERE to review our peer review and journal policies.

Prepare text of manuscripts, double spaced, in Microsoft Word. The order of items in the manuscript is: title page, key points,** abstract, text, acknowledgments, authorship confirmation statement, author disclosures, references, and correspondence address. Number each page, including the title page, consecutively.
(**Key Points are required for only Research and Review submissions.)

FILE NAMING

Label all file names with the corresponding author’s last name followed by the file type (i.e.: (JonesMainText; JonesTables; JonesFig1; JonesFig2). Use only alphanumeric characters; do not use spaces, symbols or underscores.

CLICK HERE to see STUDY DESIGN AND ETHICS REQUIREMENTS AND APPROVALS

CREATE AN EFFECTIVE TITLE

  • Manuscript titles should be brief, contain key terms, and clearly identify the purpose of the work
    conducted
  • Manuscript titles should not exceed 15-18 words. Exceptions can be made with the Editor’s approval
  • Manuscript titles should be direct and to the point. Remember that the journal has a global readership, so clear and concise non-vernacular language is most effective
  • Avoid the use of specific locations in the title
  • Do not use proprietary/trademarked names in the title
  • Do not use acronyms in the title unless they are universally recognized and accepted

NOTE:  The title page of your submission must be included as part of your main text document (not as a separate file).

TEXT

  • CLICK HERE for article types, and word / figure / table / reference limits
  • In general, the text should be organized under the headings: Introduction, Materials and Methods, Results, Discussion, and Conclusions.
  • Use only standard abbreviations, which can be found in the AMA’s Manual for Authors & Editors, 10/e. 
  • At first usage of a defined term in the abstract and then again at the first usage in the text, spell out full terminology followed by its abbreviation(s) in parentheses. Thereafter, use only the abbreviation.
  • Use generic names for drugs if possible. If you wish to use a proprietary drug name, provide it the first time it    appears, followed by the generic name and manufacturer in parentheses. Use the generic name in all subsequent places.

ACKNOWLEDGMENTS

The author should acknowledge only those people and their institutions that have made significant contributions to the study. CLICK HERE to view AUTHORSHIP QUALIFICATIONS AND RESPONSIBILITIES for definitions and detailed information.

AUTHOR CONFIRMATION STATEMENT(S) AND DISCLOSURE STATEMENTS

CLICK HERE to see REQUIRED CONTENT IN MANUSCRIPT SUBMISSIONS in our Policies Section

FUNDING INFORMATION

CLICK HERE to see OPEN ACCESS / FUNDING INFORMATION in our Policies Section

IMPORTANT: Please upload individual files of all manuscript material as described herein — do NOT upload a single PDF file containing all files for the paper. Once all appropriate files are uploaded to Manuscript Central, the system will automatically create a single PDF proof for the peer-review process.

REFERENCES

The reference list must be prepared double spaced in Word and numbered consecutively as they are cited in the text (using superscript numbers). References appearing for the first time in tables and figures must be numbered in sequence with those cited in the text where the table or figure is mentioned.  Use journal abbreviations as provided by PubMed/Medline. List all authors when there are six or less. When there are more than six, list the first three, followed by et al. If references to personal communications or unpublished data are used, they are not to be in the list of references. They should be referred to in the text in parentheses: (A.B. Smith, personal communication). Include among the reference any papers that have been accepted for publication but not yet published; identify the name of publication and add "In Press." The maximum number of references may not exceed 100.

Sample journal article reference styles:

  • Journal article with up to six authors:

Rahavi-Ezabadi S, Most SP, Saltychev M, Sazgar AA, Moubayed SP, Saedi B.  Validation of the Persian language version of the Standardized Cosmesis and Health Nasal Outcomes Survey (SCHNOS). JAMA Facial Plast Surg 2018;20(6):521-523.

  • Journal article with more than six authors:

Nellis JC, Ishii M, Bater KL, et al.  Association of Rhinoplasty with perceived attractiveness, success, and overall health. JAMA Facial Plast Surg 2018;20(2):97-102.

FOR USERS OF ENDNOTE

Currently, Facial Plastic Surgery & Aesthetic Medicine is not yet listed in EndNote, however, you may use this output styleNOTE:  The publisher of Facial Plastic Surgery & Aesthetic Medicine does not provide technical support for EndNote. If you have questions or need assistance, click on the Support tab on EndNote's website for assistance.

FIGURES

Figures should be numbered in the order cited in the text. Cite figures consecutively in the manuscript. Any identifying patient information must be removed and anonymized. Images should not show the name of a manufacturer. Maximum figures in a submission is six (6). See the next section for guidance on figure legends.

Please follow these guidelines for figure submission:

  • Do not include any figures or tables in the main text file
  • Do not prepare any figures in Word as they are not workable
  • Line illustrations must be submitted at a minimum of 900 DPI
  • Halftones and color photos should be submitted at a minimum of 300 DPI
  • Avoid submitting PowerPoint and Excel files
  • Save art as either TIFF or EPS files. (Avoid submitting JPEG files as their resolution is typically too low.)
  • Color art must be saved as CYMK not RGB

LEGENDS

Each supplied figure must have a figure legend. Prepare a single Word document, double spaced, of all figure legends and upload it under the file category, “Figure Legends.” Be sure to define any abbreviations, symbols, arrows, etc., that appear in the figure(s).

If a figure is being adapted or reused from a previously published source, permission from the original copyright holder must be secured, an appropriate credit line must be included in the figure legend, and the source(s) should be included in the reference list in addition to being appropriately cited within the text.

TABLES

Prepare all tables in one Word file and be sure to provide a title for each table. Cite tables in sequence in the text. Explain abbreviations used in the body of the table as table footnotes.

If a table is being adapted or reused from a previously published source, permission from the original copyright holder must be secured, an appropriate credit line must be included in the table footnotes, and the source(s) should be included in the reference list in addition to being appropriately cited within the text.

NOTE: Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)

CORRESPONDENCE ADDRESS

At the end of the manuscript, provide the name and complete address of the person to whom correspondence should be sent.

DATA SHARING

CLICK HERE to see DATA SHARING AND PREPRINT POLICIES

PERMISSIONS

Materials taken from other sources must be accompanied by a written statement from the original copyright holder allowing permission to the Journal for reproduction. Obtain and submit written permission from authors to cite unpublished data or papers still in press. Include appropriate information in corresponding figure and/or table legends, crediting the original source. Authors are responsible for securing any reused or repurposed material, as well as any fees incurred for such material.

AFTER ACCEPTANCE

CLICK HERE to see POST-ACCEPTANCE AND POST-PUBLICATION POLICIES

RESPONDING TO REPORTS OF MISCONDUCT

CLICK HERE to see RESPONDING TO ALLEGATION OF SCIENTIFIC MISCONDUCT

 

Facial Plastic Surgery & Aesthetic Medicine follows the standards, guidelines, and best practices set forth by the -Committee on Publication Ethics (COPE; publicationethics.org), the International Committee of Journal Medical Editors (ICJME; www.icmje.org), the World Medical Association (WMA); www.wma.net) and the American Medical Association (www.ama-assn.org).

Facial Plastic Surgery & Aesthetic Medicine is a single-blinded peer-reviewed journal. All submissions are subject to peer review. Upon submission, manuscripts are assessed by an editor for suitability for the journal.  For those that are deemed suitable, a minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Following peer review, the Editor and/or Associate Editors will determine if the paper should be accepted, require revision, or is unacceptable for publication.

Confidentiality in Peer Review

Editors and reviewers must maintain strict confidentiality of manuscripts during the peer-review process. Sharing a manuscript in whole or in part, outside the scope of what is necessary for assessment, is impermissible prior to an accepted manuscript's official publication date.

Sharing of Materials during Peer Review

Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review unless it violates the privacy or confidentiality of human research subjects.

Papers Authored by the Editor-in-Chief and/or Associate Editors

The Editor-in-Chief and Associate Editors will recuse themselves from participating in the review process of any manuscript in which there is a potential or actual competing interest.

Self-Citation and Self-Plagiarism

Facial Plastic Surgery & Aesthetic Medicine is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works. (Deposition of a preprint on a preprint server is not considered as prior publication and will not impact consideration of any submitted manuscript.)

Time in Review

Facial Plastic Surgery & Aesthetic Medicine aims to maintain a short, but thorough peer-review process. The average time in review is 35 days. However, the Editor(s) will strive to expedite manuscript handling if/when special circumstances dictate.

ATTENTION:  To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.
 

AUTHORSHIP

Definition of Authorship

Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria:

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Non-Author Contributors

Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged in the Acknowledgments section with a description of their contribution to the work.

For further information, visit the International Committee of Medical Journal Editors’ website at: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html

ORCID IDs

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

AUTHORSHIP LIMIT

There is a limit of 35 of authors permitted on a single submission, but in cases where there are 20 or more co-authors, Facial Plastic Surgery & Aesthetic Medicine recommends that a collective group or consortium name be provided and the individual authors listed in the Acknowledgements.

CORRESPONDING AUTHOR**

One author should be designated as the corresponding author who will be responsible for communication between the authors and the journal editorial office(s) and publisher. This individual will be responsible for ensuring all authors submit copyright forms and coordinating and responding to page proofs, as well as any managing any other necessary contact during the peer review and/or production processes.

**NOTE: Due to configuration restraints, the submission system permits only one author to be identified as the corresponding author of record. However, we recognize that some submissions call for more than one corresponding author to be noted. In such cases, select one author to be the main point of contact and/or corresponding author for all communications regarding the peer review process of the paper, but on the title page of the manuscript, designate additional co-corresponding authors by including an asterisk after the authors' names in the byline, and include an accompanying footnote on the title page that reads, "*Co-corresponding authors."  Please ensure that the title page of the submission page carries the full affiliation details and email addresses of all authors who should be noted as a corresponding author. If the paper is accepted for publication, the full contact information for all desginated co-authors will be listed at the end of the article as per usual journal style.

WORKING GROUPS / TEAM AUTHORSHIP

Working Groups or Teams may be listed in the manuscript byline, but the entire listing of names and affiliations should be included in the acknowledgment section of the manuscript. Do not list the names in a footnote on the title page.

VARIATIONS OF AUTHORSHIP

It is permissible to list up to three authors as co-first authors, or as contributing equally to the work. Include an asterisk (*) next to the authors' names who are considered as first authors. Include a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors."

CHANGES IN AUTHORSHIP

Changes in authorship after submission or acceptance of a paper are strongly discouraged, but the editorial leadership recognizes that in certain circumstances, it may be required. The journal's policy for such cases is as follows:

  • A request to alter authorship must be made in writing from the corresponding author to the Editor-in-Chief, with a detailed explanation for the request, and the names and affiliations of the authors requiring addition and/or deletion.
  • Authorship may be altered after submission or acceptance of a paper ONLY with the expressed written approval of all authors named on the manuscript, as well as the individual(s) being added and/or deleted. The Publisher can provide a form for this, if needed.
  • Upon receipt of the request and all written approvals of all involved parties, the Editor-in-Chief will consider the request, render a decision, and notify the corresponding author.
  • There is a one-year post-publication statute of limitation on requests for alterations in authorship.
  • Post-publication changes or alterations to conference abstracts are prohibited.

ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

EXCLUSIVITY

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of a conference abstract.  If work was presented at a conference, supply the name, date, and location of the meeting as a footnote on the title page of the submission.

AUTHOR DISCLOSURE STATEMENTS

  • Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
  • Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
  • Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
  • Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
  • Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

SELF-CITATION AND SELF-PLAGIARISM

Facial Plastic Surgery & Aesthetic Medicine is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

AFFILIATIONS

Authors should identify as their institution(s) the facility where the work was performed and executed.  Changes in an author’s affiliation after the work was completed but prior to the submission or publication of the manuscript should be noted by including an asterisk as a superscript to the name in the author listing, as well as a corresponding footnote on the title page indicating “Current Address” listing the new affiliation.   Corrections to affiliations or contact information due to relocation after publication is not permitted.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

INTERNAL REVIEW BOARD APPROVALS/WAIVERS

(As described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.


If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.

ETHICS OF EXPERIMENTATION

All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (http://ethics.od.nih.gov/).

ETHICAL TREATMENT OF ANIMALS

All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.

For further information, consult the World Medical Association’s website: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

NOTE:  Word limits do not pertain to the manuscript title, authors, affiliations, abstract, acknowledgments, disclosure statement(s), author confirmation statement(s), figure legends, tables, references, appendices, or supplemental online-only material. 

Original Investigation Papers:

Clinical Trials   •   Meta-analysis  •   Intervention Study  •   Cohort Study  •   Case-control Study  •   Epidemiologic Assessment  •   Survey with High Response Rate   •   Cost-effectiveness Analysis  •   Decision Analysis  •   Study of Screening and Diagnostic Tests  •   Other observational studies

  • 3,000 words
  • No more than 5 tables and/or figures
  • Structured abstract (maximum of 250 words)
  • Key Points  (In the manuscript, include a separate section called "Key Points" before the Abstract. This feature provides a quick structured synopsis of the findings of your manuscript (required only for research and review manuscripts),following 3 key points: Question, Findings, and Meaning. Limit this section to 75-100 words or less.)
  • Follow Equator Reporting Guidelines

Research Letter:

Concise, focused reports of original research. Can include any of the study types listed under Original Investigation.

  • 600 words
  • No more than 7 authors
  • Maximum of 6 references
  • Maximum of 2 figures and/or small tables

Systematic Review (without meta-analysis)

Critical assessments of the literature and data sources pertaining to clinical topics, emphasizing factors such as cause, diagnosis, prognosis, therapy, or prevention.

  • Systematic Reviews without meta-analysis are published as Reviews; those with meta-analysis are published as Original Investigations (see Meta-analysis under Original Investigation Papers).
  • 3,500 words
  • 50-75 references
  • 5 tables and/or figures
  • A PRISMA-style flow diagram should be included as an online supplement
  • Include a table with ratings of the quality of the studies/evidence
  • Subtitle should be "A Systematic Review"
  • Structured abstract
  • Follow Equator Reporting Guidelines  

Advances in Diagnosis and Treatment Review

A complete systematic review of the last 5 years of published literature focusing on the latest information about management of diseases and conditions, emphasizing what is new; typically written by senior experts in the field.

  • These reviews should address a specific question or issue that is relevant for clinical practice.
  • Maximum 3,500 words
  • 50-75 references
  • Maximum of 5 tables and/or figures
  • A PRISMA-style flow diagram should be included as an online supplement
  • Include a table with ratings of the quality of the studies/evidence
  • Subtitle should be "Advances in Diagnosis and Treatment"
  • Structured abstract
  • Follow Equator Reporting Guidelines

Narrative Review
Up-to-date review for clinicians on a topic of general common interest from the perspective of internationally recognized experts in these disciplines.

  • The focus should be an update on current understanding of the physiology of the disease or condition, diagnostic consideration, and treatment.
  • Subtitle should be "A Review"
  • These reviews should address a specific question or issue that is relevant for clinical practice.
  • 2,000-3,500 words
  • 50-75 references
  • No more than 5 tables and/or figures
  • 3-part structured abstract:
    Narrative Review articles should include a 3-part structured abstract of no  more than 250 words using the headings listed below:
    • Importance: An overview of the topic and discussion of the main objective or reason for this review.
    • Observations: The principal observations and findings of the review.
    • Conclusions and Relevance: The conclusions of the review that are supported by the information, along with clinical applications. How the findings are clinically relevant should be specifically stated.

Special Communications
This journal publishes very few of these types of articles.

  • These manuscripts describe an important issue in clinical medicine, public health, health policy, or medical research in a scholarly, thorough, well-referenced, systematic, and evidence-based manner.
  • 3,000 words
  • Unstructured abstract of 200 words or less
  • 50 references
  • No more than 4 tables and/or figures

Clinical Challenge

Presents an actual patient case with a specific disease or condition with an accompanying clinical image.

  • Features "What Would You Do Next?"
  • "What Would You Do Next?" with 4 single-phrase plausible treatment options describing possible courses of action with 1 being preferred
  • Case presentation: 250 words
  • Discussion: 500-600 words
  • Maximum of 10 references
  • No more than 3 authors
  • 1-2 small figures
  • Patient permission may be needed

Surgical Pearls

A video snapshot and a short description of a surgical technique

  • Maximum of 800 words
  • 1 video
  • 1-2 figures
  • No more than 7 references
  • No more than 3 authors
  • Patient permission may be needed

Viewpoint

May address virtually any important topic in medicine, public health, research, discovery, prevention, ethics, health policy, or health law and generally are not linked to a specific article.
1,200 words (or 1,000 words with 1 small table or figure)

  • No more than 7 references at submission
  • No more than 3 authors, with no more than 2 affiliations per author

Letters to the Editor

Letters discussing a recent article in this journal should be submitted within 4 weeks of the article's publication in print.

  • 500 words
  • No more than 4 references (1 of which should be to the recent article)
  • No more than 3 authors

Responses to Letters to the Editor

Replies by authors of original articles to letters from readers

  • 500 words
  • No more than 6 references
  • No more than 3 authors

Observation

Short reports of 1 or 2 complicated or unique cases.

  • 600 words
  • No more than 7 authors
  • Maximum of 6 references
  • 2 small tables and/or figures
  • No online-only material
  • Patient permission may be needed

AUTHOR DISCLOSURE STATEMENTS

  • Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
  • Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
  • Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
  • Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
  • Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

INTERNAL REVIEW BOARD APPROVALS/WAIVERS

(As described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.


AUTHORSHIP CONFIRMATION STATEMENT(S)

On a separate page within the manuscript file, include a paragraph detailing each listed authors’ contributions to and responsibilities for the manuscript. This text should also contain a statement that all co-authors have reviewed and approved of the manuscript prior to submission.

 

 

COPYRIGHT AGREEMENT FORM

Upon acceptance of any manuscript, all authors will receive an email with detailed instructions and a unique, author-specific link to access and complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors' email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications. FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM WILL RESULT IN A DELAY OF PUBLICATION. The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright. Copyright forms may also be completed by logging in to the system using an author's credentials. After logging on, click on Author Center and complete the forms located under "Manuscripts I Have Coauthored."

Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc., unless alternate arrangements are made prior to publication, including CC-BY licensing (see below). By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.

OPEN ACCESS / CC-BY LICENSING

Facial Plastic Surgery & Aesthetic Medicine is a subscription-based peer-reviewed journal with Open Access options. Creative Commons CC-BY and CC-BY-NC licensing is available for all articles published open access for a standard Article Processing Charge (APC). Please contact our Open Access Manager for pricing information and to order open access for your article. Learn more about open access publishing on our website.

PERMISSIONS

When reproducing copyrighted material such as figures, tables, or excerpted text, the author(s) of the submitted paper must obtain permission from the original publisher and submit it concurrently with the manuscript. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al." and list the appropriate reference. All permissions must be supplied at the time of submission.  Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.

REUSE OF MATERIAL POSTED ON SOCIAL MEDIA

As material posted on social media platforms is usually not peer-reviewed content, it is not permitted as an official citation and/or reference.

DATA SHARING

Facial Plastic Surgery & Aesthetic Medicine strongly advocates the sharing and archiving of the data and any other artifacts that define and support the results stated in a manuscript in a suitable public repository (in accordance with valid privacy, legal, and ethical guidelines). A data availability statement should be included in the manuscript (in the Methods section or as a separate section at the end of the manuscript), describing the location of the data, with details on how it can be accessed as well as any licensing information. If the data is not publicly available or accessible, that information should also be provided.

Datasets should be cited in the reference list by Author (Year). Title. Publisher. Identifier/DOI.

Important: Please check with your funding agencies to ensure that are you following their data sharing polices. If your funding agency has additional requirements exceeding our policy, you must follow the requirements of your funder.

PREPRINT SERVERS

A preprint is a complete draft of a research paper that is shared on a public preprint server prior to submission to a journal for peer review.
 
Mary Ann Liebert, Inc., allows for papers that were previously deposited on preprint servers to be submitted to our journals, with the proviso that the author updates any preprint versions with a link to the final published article.  All submissions are subject to peer review and allowing the submission of preprint manuscripts does not guarantee publication in any Mary Ann Liebert, Inc., journal.
 
The submitting author of a paper that was previously deposited to a preprint server should include a disclosure on the title page of the manuscript indicating the name and website of the server and include the DOI number of the preprint.
 
Referencing/citing non-peer-reviewed material that is found on any preprint server is generally discouraged by Mary Ann Liebert, Inc., journals, but if it is necessary, the citation must make it clear that the content is not officially published in a journal, and can only be found on a preprint server.

 

RESEARCH FUNDER COMPLIANCE (FundRef)

Upon submission of a manuscript, the submitting agent will have an opportunity to enter funding/grant information. If funding information is entered correctly, the publisher will deposit the funding acknowledgements from the article as part of the standard metadata to FundRef. The entered information should include funder names, funder IDs (if available), and associated grant numbers.  Special care should be taken when entering this information to ensure total accuracy. (See https://www.crossref.org/services/funder-registry/ for a listing of more than 13,000 international funding agencies.)

GOVERNMENT FUNDED RESEARCH

Facial Plastic Surgery & Aesthetic Medicine is fully NIH-, HHMI-, RCUK, and Wellcome Trust-compliant.

OPEN ACCESS

Our open access publishing solutions allow you to comply with the open access policies of your institution, government, and funding body. If you are employed or funded by the National Institute of Health (NIH), the Wellcome Trust, Research Councils UK (RCUK), or Howard Hughes Medical Institute (HHMI), you can find more information below:

  • NIH and HHMI Public Access Policy–In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final paginated version of the published article to PubMed Central (PMC) on behalf of the authors after a 12-month embargo period. Authors need not take any action. This service is provided free of charge. Authors who wish to remove the 12-month embargo period are encouraged to consider publishing with Open Option.
  • Wellcome Trust Policy–To easily comply, you can choose to have your article published open access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the Wellcome Trust.
  • Research Councils UK (RCUK)–To easily comply, you can choose to have your article published Open Access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the RCUK.

ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

POST-ACCEPTANCE / PRODUCTION

The typical time between acceptance of a paper and page proof distribution is approximately 3-6 weeks depending on the length and complexity of the paper, and the timing of the corresponding author's responses to page proofs.

 

All accepted manuscripts will go through copyediting, typesetting, figure sizing and placement, author proofing, corrections, revisions (from corrected proofs), online-ahead-of-print release, and lastly, issue assignment. Changes or alterations to a submission are not permitted after acceptance, but should be addressed in page proofs.

PAGE PROOFS

Page proofs will be sent to the corresponding author as designated in Manuscript Central when the manuscript was submitted. It is the corresponding author's responsibility to share the page proofs with co-authors, if desired, and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors/sources.

AUTHOR RESPONSE TO GALLEY PROOF

  • The corresponding author is responsible for returning corrected galley proofs generally within 72 hours of receipt.
  • If the corresponding author does not respond within that timeframe, the manuscript may be delayed in the publication schedule, or published as is, at the discretion of the Editor and Publisher.
  • If the corresponding author expects to be unavailable during the time the manuscript is in production, the publisher should be provided with an alternate contact. 
  • Only corrections directly related to errors in typesetting and/or layout will be allowed.
  • Any requested changes related to content, or that alter the outcome of a study, will require the approval of the Editor, and may require further peer review.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

POST-PUBLICATION CORRECTIONS

In the event an error is discovered after publication of an article, the corresponding author should submit the correction in writing to the editorial office for consideration.  After editor approval, alterations will be made to the online version of the article, and if the errors are significant, an official correction statement will be issued.

  • Changes to author affiliations or contact details due to relocation after publication are not permitted.
  • Corrections to meeting abstracts will be made only to the online version.  The Journal does not issue formal correction statements for corrections to meeting abstracts, regardless of the nature of the correction.
  • Correction Statements/Errata to published articles that require the reproduction of color figure(s) and/or table(s) may incur additional costs to the author(s).

RETRACTIONS**

Facial Plastic Surgery & Aesthetic Medicine and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction.

**Any paid publication fees for retracted and/or withdrawn articles are nonrefundable in any circumstance.

STUDY DESIGN AND ETHICS

RESPONDING TO ALLEGATIONS OF POSSIBLE MISCONDUCT

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.

DEFINITIONS OF SCIENTIFIC MISCONDUCT

Mary Ann Liebert, Inc., publishers follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  • Authorship Disputes: Deliberate misrepresentation of a scientist's contribution to the published work, or purposefully omitting the contributions of a scientist.
  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
  • Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
  • Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  • Plagiarism: Purposely claiming another's work or idea as your own constitutes misconduct and/or fraud.
  • Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.

RETRACTIONS

The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction.

JOURNAL FEES

  • There is no submission fee for Facial Plastic Surgery & Aesthetic Medicine.
  • Please contact AuthorBenefits@liebertpub.com for costs for publishing images in color.
  • Open Access and Creative Commons (CC-BY / CC-BY-NC) licensing options are available. Contact our Open Access Manager for more information.
  • For pricing and purchasing reprints, contact our Reprints Manager.
  • Any fees collected or payments associated with a submitted and/or published paper that is subsequently withdrawn and/or retracted for any reason are non-refundable.

 

Three versions of the article format versions are referenced in the below policy guidelines:

•    Original Submission: The article version that is submitted by the author for consideration, before peer review.
•    Accepted Version: The article version that has been formally accepted after peer review, prior to any typesetting for the journal. This is the version accepted by the editor, before proofs, corrections, and typesetting. Also known as the “raw” accepted version of a manuscript.
•    Article of Record: This article version is the “version of record” that has been formally copyedited, typeset, and published online epub ahead of print and/or in a journal issue. It is the same version published in the “Online Now” section of the journal website.

Self-Archiving Policy

Mary Ann Liebert, Inc., publishers offers authors many options and opportunities to self-archive their work. Self-archiving of work is also referred to, or known as, publishing “Green Open Access”.

Authors can self-archive the original submission version of their article on any website or repository without embargo.

Additionally, authors can self-archive the accepted version of their article on their personal websites or institutional repositories only, without embargo. Any archiving of the accepted version for inclusion in subject-based repositories, such as PubMed Central (PMC), should follow the requirements of the funder of the work.  

Authors are not allowed to publish or self-archive the article of record on any website, social media platform, or repository without permission from Mary Ann Liebert, Inc., publishers, unless they publish their paper Gold Open Access (OA). Learn more about publishing your work Open Access here.

Mary Ann Liebert, Inc., publishers’ society partners or associated affiliates may set self-archiving policies independently, outside of the below -mentioned general policies. Authors should refer to the copyright policy of their chosen journal, which can be found on the Journal Collection Page or by contacting the specific journal editorial office directly. In addition, specific funding organizations have separate agreements and authors should refer to the policies of those specific funding agencies prior to the submission of their manuscript.

Original Submission Version

The original submission version of an article is the author's version that has not been peer reviewed.

This version may be placed on:

•    The author's personal website
•    The author's company or institutional repository or archive
•    Any not-for-profit subject-based preprint servers or repositories

Self-archiving of the original submission version is not subject to an embargo period.

If your submission is formally accepted after peer review in one of our journals, authors must include an acknowledgement of acceptance for publication on all archive sites and, following online publication, authors must include the following notice on the first page:

This is the original submission version (pre-peer review) of the following article: [full citation], which has now been formally published in final form at Facial Plastic Surgery & Aesthetic Medicine at [link to final article using the DOI]. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

The original submission version posted may never be updated or replaced with the article of record version unless the author chooses to publish their paper OA under any of the Creative Commons Licenses available through the publisher. If you are interested in publishing your work OA, please feel free to review our Open Access policies and Licenses or contact us.

Accepted Version

Authors may only archive the accepted version of their manuscript on their personal and professional websites, and/or the author’s institutional repository or archive. Any archiving of the accepted version for inclusion in subject-based repositories, such as PubMed Central (PMC), should follow the requirements of the funder of the work. This process may impose additional embargo periods.  

The accepted version may be placed on:
•    The author's personal website
•    The author's company/institutional repository or archive

The accepted version posted must include the following notice on the first page:

This is the accepted version of the following article: [full citation], which has now been formally published in final form at Facial Plastic Surgery & Aesthetic Medicine at [link to final article using the DOI]. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

The posted accepted version may never be updated or replaced with the article of record version unless the author chooses to publish their paper Open Access under any of the Creative Commons Licenses available through the publisher. If you are interested in publishing your work OA, please feel free to review our Open Access policies and Licenses or contact us.

Article of Record

The article of record version may never be archived on a website, or in a repository or research network, unless published Gold Open Access under any of the Creative Commons Licenses available through the publisher. If you have questions, please contact us for more information. You can also review our Open Access policies and Licenses.

Funder Requirements

Mary Ann Liebert, Inc. publishers adheres to national and international funder requirements. Various funders, such as the National Institutes of Health (NIH), Wellcome Trust, Howard Hughes Medical Institute (HHMI), The Bill & Melinda Gates Foundation, and UK Research and Innovation (UKRI), for example, have specific requirements for depositing the accepted version and/or the article of record version of the author manuscript in a repository after an embargo period. Authors funded by these organizations should follow the self-archiving terms and conditions of these separate agreements based on the policies of the specific funding institutions. If you have questions, please contact us for more information.

Terms and Conditions for Use of All Self-Archived Article Versions

Authors may use either the original submission version or accepted version in the following ways:

•    For purposes of your own curriculum or teaching, dissertation, thesis, or book provided that all posted versions include the aforementioned notices, and follow all guidelines and requirements specified.
•    To share with researchers and research colleagues provided that such sharing is not for commercial purposes.

The self-archived submitted and accepted versions may only be used in non-commercial capacities. Individual users may view, print, download, and copy self-archived articles, as well as text and data mine the content conditions for non-commercial and non-promotional research and private study purposes, under the following requirements:

•    The authors' moral rights are not compromised and there is clear "attribution" of the author(s) in the shared work.
•    The authors’ integrity remains intact; the work should never be altered in such a way that the author's reputation or integrity may be damaged.
•    Any reuse complies with the copyright policies of the owner of that content.
•    Self-archived content may never be republished verbatim in whole or in part in print or online formats.

 

 

The Office of Foreign Assets Control (OFAC) of the US Department of the Treasury administers and enforces economic and trade sanctions based on US foreign policy and national security goals against targeted foreign countries and regimes, terrorists, international narcotics traffickers, those engaged in activities related to the proliferation of weapons of mass destruction, and other threats to the national security, foreign policy or economy of the United States. (Source: https://www.treasury.gov/about/organizational-structure/offices/pages/office-of-foreign-assets-control.aspx)

Our journal editors welcome contributions from researchers around the world; however, they are also required to follow sanction laws and regulations. Upon the date of this update (August 2020), sanction measures imposed by the United States, United Nations, European Union, and Australia are currently in place against the following countries: Cuba, Crimea, Iran, North Korea, and Syria. Journal editors will treat with caution any submission from a sanctioned country regarding the subject matter and will seek appropriate legal advice from the publisher if necessary.

Papers from sanctioned countries that are submitted to any Mary Ann Liebert, Inc., journal MUST contain a confirmation statement after the conclusion section of the manuscript which indicates that EACH listed author confirms that their research is supported by an institution that is primarily involved in education or research.

For further questions, please contact our Director of Production and Editorial Operations.

Mary Ann Liebert, Inc., publishers permits the use of accepted pre-published manuscripts for the sole purpose of pitching to news organizations under strict embargo, and with the approval of and expressed collaboration with the publisher. A watermarked PDF version of the article (not a Word document or any other editable version) may be shared only with named, personal contacts at trusted news sources upon request. News sources must be informed upon delivery of the PDF that the manuscript is for reference-only purposes and can be used only in preparation of their news coverage of the article. It is strictly prohibited to publicly share, post, or otherwise distribute the PDF in any media format. Upon official publication of the article, news organizations must link directly to the published article on the publisher’s journal website. To coordinate publication timing and press efforts, please contact the Director of Marketing, Kathryn Ryan (kryan@liebertpub.com).

ARCHIVING AND PRESERVATION

Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Your article will be easily searchable on Google, Google Scholar, and other search engines.

PUBLISHER

Facial Plastic Surgery & Aesthetic Medicine is published by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801; Tel: 914-740-2100; Email: Info@liebertpub.com; Website: www.liebertpub.com/FPSAM

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Upcoming Events

Feb 04 - Feb 07, 2021